HYPOFIBRINOGENEMIA IN BLEEDING CARDIAC SURGERY: A PROBLEM IN DISGUISE

Dr. Worasak Keeyapaj, Stanford University

Excessive post-operative hemorrhage in cardiac surgery is known to result in substantial increases in postoperative complications such as need for re-exploration, prolonged ICU stay, ventilation for >24 hours, need for any kind of blood products and associated risks, and increased mortality.1 Several professional societies have published protocols for assessing coagulopathy and optimizing blood component replacement aiming to stop bleeding as quickly as possible. A 1:1:1 transfusion ratio of red cells to platelets to plasma shows a benefit for massive hemorrhage treatment in cardiovascular surgery.2 A targeted (goal directed) transfusion algorithm promotes individual component therapy with concentrated clotting factors instead of a fixed ratio transfusion in cardiac surgery. Fibrinogen, the precursor for fibrin, a key protein in clot formation, is the first clotting factor to reach critically low levels during hemorrhage.3

> continued on page 2

WINNING WITH A NOVEL STATISTICAL ANALYSIS IN CT TRIALS: USE OF THE WIN RATIO

Kevin W. Lobdell, Sanger Heart & Vascular Institute, Atrium Health, Charlotte, NC
Andrew D. Shaw, Cleveland Clinic, Cleveland, OH
Andre Lamy, Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada

RBT-1 is a novel preconditioning drug being developed to prevent postoperative complications in patients undergoing cardiothoracic surgery. It activates various antioxidant, anti-inflammatory, and iron-scavenging pathways and, when administered

> continued on page 3

POST-OPERATIVE ATRIAL FIBRILLATION: CLINICAL IMPLICATIONS, GUIDELINES, AND EMERGING EVIDENCE

Marc W Gerdisch MD
Loyola University Medical Center, Chicago, IL

New-onset post-operative atrial fibrillation (POAF) occurs in 20-50% of patients after cardiac surgery. POAF usually develops within the index hospital stay and often extends it. Post-discharge POAF may be underdiagnosed. POAF is not a benign condition: it confers a 5- to 8-fold risk of AF recurrence1,2 and has been associated with increased risks of stroke and mortality, as demonstrated by large meta-analyses.3,4 POAF reveals atrial myopathy and atrial myocardial substrate vulnerable to fibrillation. The substrate for AF exists before the episode of POAF and of course, persists as a durable risk. Thus, lessening the likelihood of POAF with temporary drug therapy or inflammation reduction may not confer substantial long-term protection.

The ESC/EACTS gave a 2020 Class I (Level of Evidence [LOE] A) recommendation for peri-operative amiodarone or beta-blockers for POAF prevention, whereas a 2a recommendation (LOE B) was given by ACC in 2023. However, these drugs may be underutilized in part due to side effects, including bradycardia, or real-world use compliance. Long-term

> continued on page 4

ERAS PROGRAM IN THE SPOTLIGHT

THE I HATE INFECTIONS TEAM (#IHIT)

Mike Modrow PA-C
WakeMed Health, Raleigh NC

Enhanced recovery after heart surgery (ERAS®) must include infection prevention strategies.1 WakeMed’s cardiac surgery service line developed a robust, multidisciplinary infection prevention team to evaluate and act in all phases of perioperative care to achieve a cardiac surgery DSWI rate of zero. We call this team the I Hate Infections Team2. Patient-related interventions consisted of preoperative methicillin-resistant Staphylococcus aureus identification, individualized perioperative antibiotics, antimicrobial dosing strategies, and maintenance of normothermia. Operative-related interventions involved glycemic control, sternal adhesives, medications and hemostasis, rigid sternal fixation for high-risk patients, chlorhexidine gluconate dressings over invasive lines, and use of disposable health care equipment, where able, to prevent cross contamination.

> continued on page 5
Pre-operative fibrinogen levels in cardiac surgery are independently associated with post-operative blood loss and re-exploration. Similarly, post-operative fibrinogen levels below 200 mg/dL are an independent risk factor for severe hemorrhage.

Early identification and prompt treatment of hypofibrinogenemia by viscoelastic testing or laboratory testing is associated with reduced blood component utilization and improved mortality rates in cardiovascular surgery. The common treatments for acquired hypofibrinogenemia are cryoprecipitated AHF and fibrinogen concentrate. Cryoprecipitated AHF replenishes fibrinogen as well as von Willebrand factor (vWF), factor VIII and factor XIII, whereas fibrinogen concentrate contains only fibrinogen. Risk of infection transmission delaying treatment due to thawing time and high wastage due to its short shelf-life (4-6 hours) are limitations of cryoprecipitated AHF. The high cost and lack of other clotting factors are the drawbacks of fibrinogen concentrate. Factor XIII promotes the cross-linkage of fibrin monomer into fibrin polymer and strengthens the blood clot. The result of FIBRES trial showed the efficacy of fibrinogen concentrate was non-inferior to cryoprecipitated AHF in bleeding cardiac surgical patients with hypofibrinogenemia. However, the REPLACE trial showed fibrinogen concentrate administration in bleeding cardiac surgical patients was associated with increased allogenic blood transfusion. Recently, pathogen reduced cryoprecipitated fibrinogen complex (Cerus®, Concord, CA) has been introduced as an alternative treatment option for hypofibrinogenemia. It can be stored in thawed-form, ready-to-transfuse, for up to 5 days and in addition to fibrinogen, contains other clotting factors such as vWF and factor XIII. Early detection and prompt treatment of acquired hypofibrinogenemia in bleeding cardiac surgical patients with a concentrated source of fibrinogen may reduce adverse outcomes associated with hemorrhage.

HYPOFIBRINOGENEMIA IN BLEEDING CARDIAC SURGERY: A PROBLEM IN DISGUISE

Dr. Worasak Keeyapaj, Stanford University

>> continued from page 2


WINNING WITH A NOVEL STATISTICAL ANALYSIS IN CT TRIALS: USE OF THE WIN RATIO

Kevin W. Lobdell, Sanger Heart & Vascular Institute, Atrium Health, Charlotte, NC

Andrew D. Shaw, Cleveland Clinic, Cleveland, OH

Andre Lamy, Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada

>> continued from page 1

1-2 days prior to surgery, could potentially improve clinical outcomes across various organ systems, including the heart, lung, kidneys, liver, and brain, based on preclinical data. A recently completed Phase 2 study met the primary endpoint of a cytoprotective multi-organ benefits, even if small, could add to meaningful improvement in overall outcomes (akin to the concept of “the aggregation of marginal gains” by Dave Brailsford). Quantification of such outcomes requires using a relevant composite endpoint. As such, a post-hoc analysis was performed in the Phase 2 study of RBT-1 using the Finkelstein-Schoenfeld method (win ratio), wherein clinical outcomes were assessed in a severity-based hierarchy (death > AKI requiring dialysis > ICU days > 30-day cardiopulmonary readmission). This analysis showed that patients treated with RBT-1 had improved outcomes compared to placebo and formed the basis of RBT-1 receiving a Breakthrough Therapy designation by the US FDA, as well as the agency’s agreement on a hierarchical composite endpoint for the upcoming Phase 3 RBT-1 clinical trial.

The win ratio's hierarchical structure, flexibility and statistical power (every placebo patient is compared to every treatment patient) make it an attractive approach for determining efficacy of randomized treatments. Lack of familiarity of the win ratio among clinicians and regulatory entities may have slowed its initial utilization and broad adoption in clinical trial design, however change is afoot. This novel endpoint approach, which allows multi-organ benefits to be examined across continuous and binary variables based upon severity, could form the basis of future clinical trial designs in cardiac surgery.

1. Lamy A et al. A Randomized, Blinded, Multi-Center, Phase 2 Trial of RBT-1 Versus Placebo Evaluating Cytoprotective Biomarkers and Postoperative Outcomes in Patients Undergoing Elective Coronary Artery Bypass Graft and/or Valve Surgery on Cardiopulmonary Bypass. AATS 2023 Annual Meeting –Late-Breaking Abstract.


In summary, the increased morbidity and mortality associated with POAF are well-documented. Research on various prophylactic interventions to prevent POAF continues but underscores the importance of peri-operative rhythm/rate control combined with long-term rhythm monitoring for at-risk patients.


RESEARCH ON VARIOUS PROPHYLACTIC INTERVENTIONS TO PREVENT POAF CONTINUES BUT UNDERSCORES THE IMPORTANCE OF PERI-OPERATIVE RHYTHM/RATE CONTROL COMBINED WITH LONG-TERM RHYTHM MONITORING FOR AT-RISK PATIENTS.

at index procedure. Prophylactic radiofrequency ablation of the left atrium has recently been published with evidence of decreased POAF.

Because substrate is modified, it has the potential to translate into longer term AF reduction. Myocardial inflammation reduction has been explored with colchicine or posterior pericardiotomy, which recently received a 2a (LOE B) ACC recommendation for POAF reduction. Prophylactic exclusion of the left atrial appendage (LAA), the predominant site of thrombus in AF, has been evaluated in feasibility and retrospective studies. LeAAPS (NCT05478304) is an ongoing prospective, multi-center, randomized, superiority trial to evaluate the effectiveness of LAAE for the prevention of ischemic stroke or systemic arterial embolism in non-AF cardiac surgery patients who have risk factors for AF and ischemic stroke.

To learn more about our organization, including our board members and upcoming meetings:

www.erascardiac.org
Environment-related interventions included optimizing operating room ventilation and terminal cleaning, reducing airborne particle counts, and decreasing OR foot traffic. We even now have an after-discharge care plan in place called Tele Heart Care. This program affords for a minimum of two additional APP touch points, prior to the patient’s follow up visit with their surgeon. This allows for real time wound evaluations, to get in front of any developing wound issues, as well as address other post discharge opportunities to adjust medications and evaluate overall post-op well-being etc.

Together, these interventions reduced the DSWI incidence from 1.6% pre-intervention to 0% for 14 consecutive months after full bundle implementation. Although the influence of each individual intervention on our DSWI remains unknown, use of this bundled infection prevention approach reduced the incidence to zero for the first 14 months after implementation at our institution. As our executive medical director, Dr. Judson Williams often states- “it is through these marginal gains that our patients benefit the most.” The ongoing challenges are continuing educational opportunities, for ever changing staffing, to minimize drift from in place practices. We are doing this through IHIT educational videos, like our ERAS® Virtual Training Center video, and continuing educational in-service opportunities. Of course the above interventions clearly are not all inclusive but rather representative of an organized, multimodal, multidisciplinary approach to achieving ZERO deep sternal wounds. The effort, we believe, MATTERS to achieving optimal enhanced recovery after surgery (ERAS)! Good luck on your journey to ZERO!

2. Eliminating sternal wound infections: Why every cardiac surgery program needs an I hate infections team https://doi.org/10.1016/j.xjtc.2023.03.019
Announcing the 2024 ERAS® Cardiac Fellowship Awardee:

We are proud to announce that Busra Cangut, MD is the 2024 recipient of the Richard Engelman Cardiac Enhanced Recovery Fellowship Award. This award affords the recipient the opportunity to join the ERAS® Cardiac Executive Board in focused research, collaboration, and presentations at academic meetings. The intent is to provide an enriched experience for the awardee to gain advanced training in perioperative care of cardiac surgical patients. Awardees may also travel to expert institutions for advanced training.

Dr. Busra Cangut completed her medical school at Istanbul-Marmara University School of Medicine and pursued her basic science research year, postdoctoral fellowship, master’s degree and general surgery intern year at Mayo Clinic. She is currently working on the development of novel cardiac imaging technologies for specific valve pathologies as well as clinical outcome research at Mount Sinai Hospital/New York. Her multifaceted approach to cardiothoracic surgery, encompassing basic science, clinical, and imaging aspects, reflects her unique and holistic understanding of the field.

Beyond her outstanding research and clinical accomplishments, Dr. Cangut has demonstrated exemplary commitment, dedication, and leadership in her role as the committee chair for Women in Thoracic Surgery (WTS). Her exceptional contributions to the field have been recognized with the prestigious 2023 STSA Carpenter Scholarship, a testament to her unwavering dedication to advancing medical knowledge.

Introducing the Virtual Training Center

The Enhanced Recovery After Surgery (ERAS®) Cardiac Society strives to promote the engagement and adoption of ERAS® protocols for the cardiac surgery patients around the world. Traditionally, this has been accomplished through publications, work groups, and presentations on national and international platform from meetings and conferences hosted by the expert organizations that support the cardiac surgery perioperative continuum.

In October, the ERAS® Cardiac Society launched a new membership for the global enhanced recovery community. One of the benefits of membership is access to educational resources, materials and presentations that have been collated into a platform titled The Virtual Training Center (VTC). The VTC includes experts from all across the world providing recorded presentations on topics of ERAS®. In addition to the presentations, the society developed implementation materials for team members to utilize when developing or expanding an ERAS® program. These items are all customizable for individual institutions and have been developed by leaders whom have implemented and sustained successful ERAS® programs. Examples of the items included are an implementation checklist, a standardized patient education booklet, visual pathways for patients and healthcare teams, a PowerPoint for team education, an ERAS® coordinator job description, and a data tracking spreadsheet. The VTC will continue to evolve by adding content on a regular basis to provide the most up to date information and resources. This entire platform was designed to provide teams and individuals with the tools we wish we had when embarking on this ERAS®adventure. Our goal is to continue perfecting the surgical journey by spreading the word, supporting each other, researching, and providing evidenced based care to improve our patients’ outcomes.

Scan the QR code to sign up for the ERAS® Cardiac membership.

IN THE NEWS:

Busra Cangut, MD is the 2024 recipient of the Richard Engelman Cardiac Enhanced Recovery Fellowship Award.

Dr. Richard Engelman

ERAS® Cardiac Society Executive Board in Lisbon

The ERAS® Cardiac Society Executive Board met in Lisbon this June at the ERAS® World Congress, where they were invited to present a specialty session on innovations in cardiac surgery.

Introducing the Virtual Training Center

Amanda Rea, DNP, CRNP; University of Maryland St. Joseph Medical Center, Towson, MD
Alex Gregory, MD, Cumming School of Medicine & Libin Cardiovascular Institute, University of Calgary, Alberta, CA

The Enhanced Recovery After Surgery (ERAS®) Cardiac Society strives to promote the engagement and adoption of ERAS® protocols for the cardiac surgery patients around the world. Traditionally, this has been accomplished through publications, work groups, and presentations on national and international platform from meetings and conferences hosted by the expert organizations that support the cardiac surgery perioperative continuum.

In October, the ERAS® Cardiac Society launched a new membership for the global enhanced recovery community. One of the benefits of membership is access to educational resources, materials and presentations that have been collated into a platform titled The Virtual Training Center (VTC). The VTC includes experts from all across the world providing recorded presentations on topics of ERAS®. In addition to the presentations, the society developed implementation materials for team members to utilize when developing or expanding an ERAS® program. These items are all customizable for individual institutions and have been developed by leaders whom have implemented and sustained successful ERAS® programs. Examples of the items included are an implementation checklist, a standardized patient education booklet, visual pathways for patients and healthcare teams, a PowerPoint for team education, an ERAS® coordinator job description, and a data tracking spreadsheet. The VTC will continue to evolve by adding content on a regular basis to provide the most up to date information and resources. This entire platform was designed to provide teams and individuals with the tools we wish we had when embarking on this ERAS®adventure. Our goal is to continue perfecting the surgical journey by spreading the word, supporting each other, researching, and providing evidenced based care to improve our patients’ outcomes.

Scan the QR code to sign up for the ERAS® Cardiac membership.


UPCOMING MEETINGS:

- **Society of Critical Care Medicine Critical Care Congress**  
  San Francisco, CA  
  January 21-24, 2024

- **Society of Thoracic Surgeons 60th Annual Meeting**  
  San Antonio, TX  
  January 27-29, 2024

- **American Association for Thoracic Surgery 104th Annual Meeting**  
  Toronto, Canada,  
  April 27-30, 2024

- **Society of Cardiovascular Anesthesiologists 46th Annual Meeting**  
  Toronto, Canada  
  April 27-30, 2024

- **Evidence Based Perioperative Medicine World Congress 2024**  
  London, England  
  July 2-4, 2024

- **10th ERAS World Congress**  
  Malaga, Spain  
  September 18-20, 2024

- **European Association for Cardio-Thoracic Surgery 38th Annual Meeting**  
  Lisbon, Portugal  
  October 9-12, 2024

- **Society of Thoracic Surgeons Perioperative Medicine and Critical Care Meeting**  
  Philadelphia, PA  
  October 24-30, 2024
The mission of the ERAS® Cardiac Society is to optimize perioperative care of cardiac surgical patients through collaborative discovery, analysis, expert consensus, and dissemination of best practices worldwide.

Who We Are

The ERAS® Cardiac Society is an international non-profit organization comprised of experts from around the world, including participation from all members of the healthcare team. Led by an executive board, an advisory board, and a pool of subject matter experts, our members strive to implement enhanced recovery principles at their local institutions while advancing improved patient care internationally through collaboration, education, and dissemination of up-to-date knowledge regarding optimal perioperative care.

ERAS® Society

The ERAS® Society is an international organization with enhanced recovery guidelines for several surgical sub-specialties. Beginning as the ERAS® Study Group in 2001, team leaders Professor Ken Fearon (University of Edinburgh) and Professor Olle Ljungqvist (Karolinska Institutet) spearheaded the developments made in multimodal surgical care. The ERAS® Study Group soon discovered that there were a variety of local traditions in practice, as well as an inconsistent application of evidence-based best practices. This prompted the group to examine the process of change from tradition to best-practice. Since its inception, the ERAS® Society has expanded to include several subspecialties, emphasized the benefits of standardized best-practices across the continuum of the perioperative period, highlighted the importance of data-driven self-evaluation, and promoted the improvement of patient care.

Our Organizational Structure

Our ERAS® Cardiac Society is made up of experts from around the world, including participation from all members of the healthcare team. Our members strive to implement enhanced recovery principals at their local institutions while advancing improved patient care internationally through collaboration, education, and dissemination of up-to-date knowledge regarding optimal perioperative care. Our organization is divided into an Executive Board, Advisory Board, and a pool of Subject Matter Experts.

To learn more about our organization, including our board members and upcoming meetings:

www.erascardiac.org

Kim Pehle
Administrator,
ERAS® Cardiac Society
k.pehle@erascardiac.org
612.760.1413

Donna Frankel
Office Manager,
ERAS® Cardiac Society
donnaerasc@gmail.com
Corporate financial support will be used to promote the mission of the ERAS® Cardiac Society. We are committed to standardizing best practice surrounding the preoperative and perioperative care of cardiac surgical patients through expert consensus, review of the literature and open communication. This unrestricted support does not represent the ERAS® Cardiac Society's support or agreement to promote any pharmaceutical, device, or technology related to the sponsors.

For more information and to become a sponsor please contact:
Administrator Kim Pehle at k.pehle@erascardiac.org
EXECUTIVE BOARD

Daniel Engelman, MD  
President  
Cardiac Surgeon  
Baystate Medical Center  
USA

Michael Grant, MD  
Vice President  
Cardiac Anesthesia and Critical Care  
Medicine Intensivist  
Johns Hopkins  
USA

Alex Gregory, MD  
Secretary  
Cardiac Anesthesia Intensivist  
University of Calgary  
Canada

Kevin Lobdell, MD  
Treasurer  
Cardiac Surgeon Intensivist  
Sanger Heart & Vascular Institute,  
Charlotte, NC  
USA

Rakesh Arora, MD, PhD  
Cardiac Surgeon Intensivist  
University Hospitals (UH)  
Harrington Heart & Vascular Institute  
USA

Subhasis Chatterjee, MD  
Cardiac Surgeon Intensivist  
Baylor College of Medicine  
USA

Cheryl Crisafi MSN, RN, CNL  
Nurse Coordinator ERAS® Cardiac Society  
Baystate Medical Center  
USA

Marjan Jahangiri, MBBS, MS, FRCS, FRCS (CTh)  
Cardiac Surgeon  
St. Georges University of London  
UK

Vicki Morton-Bailey, DNP, MSN, AGNP-BC  
Director of Clinical and Quality Outcomes  
Providence Anesthesiology Associates  
USA

V. Seeunu Reddy, MD, MBA, FACS  
Cardiac Surgeon  
Centennial Heart & Vascular Center,  
USA

ADVISORY BOARD

Keith Allen, MD  
St. Luke’s Mid America Heart Institute  
USA

Ed Boyle, MD  
St. Charles Medical Center  
USA

Jessica Brodt, MD  
Anesthesiology, Palo Alto, CA  
USA

Shannon Crotwell RN, BSN, CCRN  
Sanger Heart & Vascular Institute,  
Charlotte, NC  
USA

Andre Denault, MD, PhD, FRCP, FASE, FCCS  
Montreal Heart Institute and Centre Hospitalier de l’Université de Montréal  
Canada

Joerg Ender, MD  
Heart Center  
Leipzig  
Germany

Jill Engel, DNP, FNP, ACNP, NEA-BC, FAANP  
Duke University Medical Center  
USA

Nick Fletcher, MBBS, FRCA, FFICM  
St George’s Hospital NHS Trust,  
London  
UK

Marc Gerdisch, MD, FACS, FACC  
Franciscan Health Heart Center  
USA

Serdar Gunaydin, MD, PhD  
Cardiovascular Surgery  
University of Health Sciences,  
Turkey

Sameer Hirji, MD, MPH  
Harvard Medical School, USA  
USA

Karim Jabr, CCP, LP CSSBB  
Medical Center-Navicent Health,  
USA

Lian Kah  
Assoc Professor  
Yong Loo Lin School of Medicine,  
Anesthesia  
Singapore

Ali Khoynezhad, MD, PhD, FACS, FHRSA  
Memorial Care Long Beach Medical Center  
USA

Yoan Lamarche- MD MSc FRSCS  
Montreal Heart Institute, Université de Montréal  
Canada

Gina McConnell, BSN, RN, CCRN  
ERAS® Coordinator at WakeMed Health  
USA

Gregg Nelson, MD, PhD  
University of Calgary  
Canada

Tom Nguyen, MD  
Memorial Hermann Heart & Vascular Institute  
USA

Louis Perrault, MD, PhD, FRCS, FACS, FECS  
Montreal Heart Institute, Université de Montréal  
Canada

John Pirris, MD  
University of Florida Health  
USA

Amanda Rea, DNP, CRNP  
University of Maryland St Joseph Medical Center  
USA

Eric Roseli, MD FACS  
Cleveland Clinic  
USA

Michael Sander, MD  
Uniklinikum Giessen und Marburg  
Germany

Michael Scott  
Anesthesia and Critical Care  
University of Pennsylvania,  
Philadelphia  
USA

Andrew Shaw, MD  
University of Alberta  
Canada

Christian Stoppe, MD, FAHA, RWTH  
Aachen University  
Germany

Judson Williams, MD, MHS  
WakeMed Heart & Vascular  
USA

Alex Zarbock, MD  
University Hospital Münster,  
Germany

To learn more about our organization, including our board members and upcoming meetings:  
www.erascardiac.org